ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of "Buy" by Brokerages

Shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have been given an average rating of "Buy" by the six analysts that are currently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $9.50.

Several research analysts have recently commented on PRQR shares. HC Wainwright lifted their target price on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Friday, March 14th. Citigroup raised shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective for the company in a research report on Monday, March 10th. Oppenheimer initiated coverage on shares of ProQR Therapeutics in a research report on Friday, January 10th. They issued an "outperform" rating and a $15.00 price objective on the stock. Finally, Chardan Capital reaffirmed a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a report on Friday, March 14th.

ProQR Therapeutics Stock Performance

NASDAQ:PRQR remained flat at $1.14 during mid-day trading on Wednesday. 464,845 shares of the company traded hands, compared to its average volume of 586,971. ProQR Therapeutics has a twelve month low of $1.07 and a twelve month high of $4.62. The firm has a market cap of $119.94 million, a PE ratio of -3.56 and a beta of 0.25. The stock has a fifty day simple moving average of $1.74 and a 200 day simple moving average of $2.52.

Institutional Investors Weigh In On ProQR Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Affinity Asset Advisors LLC acquired a new position in ProQR Therapeutics in the 4th quarter valued at $7,486,000. M&T Bank Corp bought a new position in shares of ProQR Therapeutics in the fourth quarter worth $330,000. BNP Paribas Financial Markets raised its stake in ProQR Therapeutics by 14.2% in the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company's stock valued at $107,000 after purchasing an additional 7,300 shares in the last quarter. Virtu Financial LLC bought a new stake in ProQR Therapeutics during the fourth quarter worth about $83,000. Finally, Platinum Investment Management Ltd. acquired a new stake in ProQR Therapeutics during the fourth quarter worth about $4,076,000. Institutional investors and hedge funds own 32.65% of the company's stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).